Core Viewpoint - A class action lawsuit has been filed against LifeMD, Inc. for allegedly overstating its competitive position and providing unrealistic financial guidance for 2025, leading to significant investor losses when the truth was revealed [3]. Company Overview - LifeMD, Inc. is headquartered in New York and specializes in providing virtual medical services and prescription delivery [2]. Lawsuit Details - The lawsuit covers investors who purchased LifeMD shares from May 7, 2025, to August 5, 2025, and claims that the company failed to disclose rising customer acquisition costs associated with its RexMD platform and its promotion of obesity medications like Wegovy and Zepbound [3]. - The complaint asserts that LifeMD's statements during the class period were materially false and misleading, lacking a reasonable basis [3]. Investor Information - Investors who acquired LifeMD securities during the class period have until October 27, 2025, to seek appointment as lead plaintiff representatives [2].

Core Viewpoint - A class action securities lawsuit has been filed against LifeMD, Inc. for alleged securities fraud affecting investors between May 7, 2025, and August 5, 2025 [1][2] Group 1: Allegations - The lawsuit claims that defendants materially overstated LifeMD's competitive position [2] - It is alleged that defendants were reckless in raising LifeMD's 2025 guidance without properly accounting for rising customer acquisition costs in the RexMD segment and related to obesity treatment drugs [2] - Defendants' statements regarding LifeMD's business, operations, and prospects are claimed to be materially false and misleading [2] Group 2: Legal Process - Investors who suffered losses during the specified timeframe have until October 25, 2025, to request appointment as lead plaintiff [3] - Participation in the lawsuit does not require serving as a lead plaintiff, and there are no out-of-pocket costs for class members [3] Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the U.S. [4]

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of LifeMD, Inc. regarding a class action lawsuit alleging that the company made materially false and misleading statements about its competitive position and financial guidance during the specified class period [1]. Summary by Relevant Sections Allegations - The complaint claims that during the class period from May 7, 2025, to August 5, 2025, LifeMD's management overstated the company's competitive position [1]. - It is alleged that the company was reckless in raising its 2025 guidance without properly accounting for increasing customer acquisition costs in its RexMD segment and related to obesity treatment drugs like Wegovy and Zepbound [1]. - As a result, the statements made by the defendants regarding LifeMD's business operations and prospects were materially false and misleading [1]. Next Steps for Shareholders - Shareholders who purchased shares of LifeMD during the specified timeframe are encouraged to register for the class action by October 25, 2025 [2]. - Upon registration, shareholders will be enrolled in a portfolio monitoring system to receive updates on the case [2]. Firm's Commitment - The Gross Law Firm is recognized for its commitment to protecting investors' rights against deceit and fraud, ensuring companies adhere to responsible business practices [3].

Core Viewpoint - The Gross Law Firm is notifying shareholders of LifeMD, Inc. regarding a class action lawsuit due to alleged misleading statements and failure to disclose critical information during a specified class period [1][3]. Group 1: Allegations - The complaint alleges that LifeMD's management materially overstated the company's competitive position [3]. - It is claimed that the defendants were reckless in raising LifeMD's 2025 guidance without properly accounting for rising customer acquisition costs in the RexMD segment and related to obesity treatment drugs like Wegovy and Zepbound [3]. - As a result, the statements made by the defendants regarding LifeMD's business, operations, and prospects were materially false and misleading [3]. Group 2: Class Action Details - The class period for the lawsuit is defined as May 7, 2025, to August 5, 2025 [3]. - Shareholders are encouraged to register for the class action by the deadline of October 25, 2025, to potentially be appointed as lead plaintiffs [4]. - Participation in the case does not incur any cost or obligation for the shareholders [4]. Group 3: Law Firm's Mission - The Gross Law Firm aims to protect the rights of investors who have suffered due to deceit, fraud, and illegal business practices [5]. - The firm is committed to ensuring companies adhere to responsible business practices and engage in good corporate citizenship [5]. - The firm seeks recovery for investors who experienced losses due to false or misleading statements that led to artificial inflation of the company's stock [5].

Core Points - The Law Offices of Frank R. Cruz announced that investors who suffered losses related to LifeMD, Inc. have the opportunity to lead a securities fraud class action lawsuit [1] - The lawsuit alleges that from May 7, 2025, to August 5, 2025, LifeMD's management failed to disclose critical information regarding the company's competitive position and customer acquisition costs, which misled investors about the company's business prospects [2] Summary by Categories Lawsuit Details - The complaint claims that LifeMD's management materially overstated the company's competitive position [2] - It is alleged that the management was reckless in raising the 2025 guidance without properly accounting for rising customer acquisition costs in the RexMD segment and costs related to obesity treatment drugs [2] - The lawsuit asserts that the positive statements made by the defendants regarding the company's operations and prospects were materially misleading and lacked a reasonable basis [2]

SAN FRANCISCO, Sept. 9, 2025 /PRNewswire/ -- A new federal securities fraud class action lawsuit has been filed against LifeMD (NASDAQ: LFMD), alleging that the telehealth company and its executives provided investors with a misleading picture of its financial health and growth prospects. The suit, filed in in the Eastern District of New York, comes after a dramatic stock price decline in August following the company's earnings report. The firm urges investors in LifeMD who suffered significant losses to ...

NEW YORK--(BUSINESS WIRE)---- $LFMD #ClassAction--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against LifeMD, Inc. ("LifeMD†or the "Company†) (NASDAQ: LFMD). Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com. On August 5, 2025, after the market closed, LifeMD reporte ...

NEW YORK, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP is notifying investors about a federal securities class action lawsuit against LifeMD, Inc. (NASDAQ: LFMD) (“LifeMD” or the “Company”). PLEASE CLICK HERE TO JOIN THE CASE AND SUBMIT CONTACT INFORMATION LifeMD, Inc. (NASDAQ: LFMD) Securities Class Action Lawsuit Class Period: May 7, 2025 – August 5, 2025Lead Plaintiff Deadline: October 27, 2025Court: United States District Court for the Eastern District of New York Allega ...

Core Viewpoint - A class action securities lawsuit has been filed against LifeMD, Inc. for alleged securities fraud affecting investors between May 7, 2025, and August 5, 2025 [1][2]. Group 1: Allegations - The lawsuit claims that defendants materially overstated LifeMD's competitive position [2] - It is alleged that defendants were reckless in raising LifeMD's 2025 guidance without properly accounting for rising customer acquisition costs in the RexMD segment and related to obesity treatment drugs [2] - As a result, statements made by defendants regarding LifeMD's business, operations, and prospects were materially false and misleading [2] Group 2: Legal Process - Investors who suffered losses during the specified timeframe have until October 25, 2025, to request to be appointed as lead plaintiff [3] - Participation in the lawsuit does not require serving as a lead plaintiff, and class members may be entitled to compensation without any out-of-pocket costs [3] Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has extensive expertise in complex securities litigation [4] - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the top securities litigation firms in the U.S. [4]

SAN DIEGO, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of persons and entities that purchased or otherwise acquired LifeMD, Inc. (NASDAQ: LFMD) securities between May 7, 2025 and August 5, 2025. LifeMD is a leading provider of virtual primary care. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating Allegations that LifeMD, Inc. (LFMD) Misled In ...